RUSSELL BROADDUS to Prognosis
This is a "connection" page, showing publications RUSSELL BROADDUS has written about Prognosis.
Connection Strength
0.395
-
CTNNB1 (beta-catenin) mutation identifies low grade, early stage endometrial cancer patients at increased risk of recurrence. Mod Pathol. 2017 07; 30(7):1032-1041.
Score: 0.040
-
Evaluation of clinical criteria for the identification of Lynch syndrome among unselected patients with endometrial cancer. Cancer Prev Res (Phila). 2014 Jul; 7(7):686-97.
Score: 0.033
-
Prospective multicenter randomized intermediate biomarker study of oral contraceptive versus depo-provera for prevention of endometrial cancer in women with Lynch syndrome. Cancer Prev Res (Phila). 2013 Aug; 6(8):774-81.
Score: 0.031
-
Identification of cancer patients with Lynch syndrome: clinically significant discordances and problems in tissue-based mismatch repair testing. Cancer Prev Res (Phila). 2012 Feb; 5(2):320-7.
Score: 0.028
-
Expression of nuclear transcription factor kappa B in locally advanced human cervical cancer treated with definitive chemoradiation. Int J Radiat Oncol Biol Phys. 2010 Dec 01; 78(5):1331-6.
Score: 0.025
-
Long-term overall survival and prognostic score predicting survival: the IMPACT study in precision medicine. J Hematol Oncol. 2019 12 30; 12(1):145.
Score: 0.012
-
Liquid biopsy assay for lung carcinoma using centrifuged supernatants from fine-needle aspiration specimens. Ann Oncol. 2019 06 01; 30(6):963-969.
Score: 0.012
-
Adjuvant combined-modality therapy for stage IIIC endometrioid and non-endometrioid endometrial cancer. Gynecol Oncol. 2019 07; 154(1):22-28.
Score: 0.012
-
Clinical and molecular characterization of early-onset colorectal cancer. Cancer. 2019 06 15; 125(12):2002-2010.
Score: 0.011
-
Molecular Landscape of ERBB2/ERBB3 Mutated Colorectal Cancer. J Natl Cancer Inst. 2018 12 01; 110(12):1409-1417.
Score: 0.011
-
Prognostic Implications of Mucinous Differentiation in Metastatic Colorectal Carcinoma Can Be Explained by Distinct Molecular and Clinicopathologic Characteristics. Clin Colorectal Cancer. 2018 12; 17(4):e699-e709.
Score: 0.011
-
Classifying Colorectal Cancer by Tumor Location Rather than Sidedness Highlights a Continuum in Mutation Profiles and Consensus Molecular Subtypes. Clin Cancer Res. 2018 03 01; 24(5):1062-1072.
Score: 0.010
-
Validation of Immunohistochemical Assays for Integral Biomarkers in the NCI-MATCH EAY131 Clinical Trial. Clin Cancer Res. 2018 02 01; 24(3):521-531.
Score: 0.010
-
Antiangiogenesis and gene aberration-related therapy may improve overall survival in patients with concurrent KRAS and TP53 hotspot mutant cancer. Oncotarget. 2017 May 16; 8(20):33796-33806.
Score: 0.010
-
Somatic mutation profiles of clear cell endometrial tumors revealed by whole exome and targeted gene sequencing. Cancer. 2017 Sep 01; 123(17):3261-3268.
Score: 0.010
-
Factors prognostic of survival in advanced-stage uterine serous carcinoma. Gynecol Oncol. 2017 07; 146(1):27-33.
Score: 0.010
-
How Do We Make Clinical Molecular Testing for Cancer Standard of Care for Pathology Departments? J Natl Compr Canc Netw. 2016 06; 14(6):787-92.
Score: 0.009
-
PTEN loss is a context-dependent outcome determinant in obese and non-obese endometrioid endometrial cancer patients. Mol Oncol. 2015 Oct; 9(8):1694-703.
Score: 0.009
-
OvMark: a user-friendly system for the identification of prognostic biomarkers in publically available ovarian cancer gene expression datasets. Mol Cancer. 2014 Oct 24; 13:241.
Score: 0.008
-
Progesterone receptor and PTEN expression predict survival in patients with low- and intermediate-grade pancreatic neuroendocrine tumors. Arch Pathol Lab Med. 2014 Aug; 138(8):1027-36.
Score: 0.008
-
The search continues: looking for predictive biomarkers for response to mammalian target of rapamycin inhibition in endometrial cancer. Int J Gynecol Cancer. 2014 May; 24(4):713-7.
Score: 0.008
-
Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H). Ann Oncol. 2014 May; 25(5):1032-8.
Score: 0.008
-
Clinicopathologic features and prognosis of duodenal adenocarcinoma and comparison with ampullary and pancreatic ductal adenocarcinoma. Hum Pathol. 2013 Dec; 44(12):2792-8.
Score: 0.008
-
Integrated analyses identify a master microRNA regulatory network for the mesenchymal subtype in serous ovarian cancer. Cancer Cell. 2013 Feb 11; 23(2):186-99.
Score: 0.008
-
Uterine serous carcinoma: increased familial risk for lynch-associated malignancies. Cancer Prev Res (Phila). 2012 Mar; 5(3):435-43.
Score: 0.007
-
Clinical and biological impact of EphA2 overexpression and angiogenesis in endometrial cancer. Cancer Biol Ther. 2010 Dec 15; 10(12):1306-14.
Score: 0.006
-
Molecular clustering of endometrial carcinoma based on estrogen-induced gene expression. Cancer Biol Ther. 2009 Nov; 8(22):2126-35.
Score: 0.006
-
EphA2 overexpression is associated with lack of hormone receptor expression and poor outcome in endometrial cancer. Cancer. 2009 Jun 15; 115(12):2684-92.
Score: 0.006
-
Clinicopathological features in endometrial carcinoma associated with Lynch syndrome in China. Int J Gynecol Cancer. 2009 May; 19(4):651-6.
Score: 0.006
-
Clinical and biological significance of vascular endothelial growth factor in endometrial cancer. Clin Cancer Res. 2007 Dec 15; 13(24):7487-95.
Score: 0.005
-
An HSP90-mimic peptide revealed by fingerprinting the pool of antibodies from ovarian cancer patients. Oncogene. 2004 Nov 25; 23(55):8859-67.
Score: 0.004
-
Her-2/neu overexpression and amplification in uterine papillary serous carcinoma. J Clin Oncol. 2004 Aug 01; 22(15):3126-32.
Score: 0.004
-
Synchronous primary cancers of the endometrium and ovary: a single institution review of 84 cases. Gynecol Oncol. 2004 Aug; 94(2):456-62.
Score: 0.004
-
Increased plasma levels of insulin-like growth factor 2 and insulin-like growth factor binding protein 3 are associated with endometrial cancer risk. Cancer Epidemiol Biomarkers Prev. 2004 May; 13(5):748-52.
Score: 0.004